Blueprint Medicines — Jefferies Healthcare Conference 2022
24 slides from Blueprint Medicines's conference presentation, Jun 9, 2022

Slide 1: Jefferies Healthcare Conference June 9, 2022
JEFFERIES HEALTHCARE CONFERENCE JUNE 9, 2022 Kristine G. Systemic mastocytosis patient Pioneering the Science of Time Not for promotional use.

Slide 2: Forward-looking statements
Forward-looking statements 2 Not for promotional use. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, timelines and expectations for interactions w

Slide 3: Blueprint Medicines is a global leader in precision therapy
Blueprint Medicines is a global leader in precision therapy AYVAKIT is approved for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations, and adult patients with advanced SM, including aggressive SM, SM with an associated

Slide 4: Blueprint is uniquely positioned with a diversity of significant growth drivers
Blueprint is uniquely positioned with a diversity of significant growth drivers Ongoing global collaboration with Roche and Genentech for the development and commercialization of GAVRETO. FDA, U.S. Food and Drug Administration; EC, European Commission; PDGFRA, platelet-derived growth factor receptor

Slide 5: Global Commercial Execution
Global Commercial Execution Cyndi N. Systemic mastocytosis patient Not for promotional use.

Slide 6: We are establishing the standard of care for advanced SM
We are establishing the standard of care for advanced SM 6 Not for promotional use. 1. Reported data represent estimations. Analysis based on US claims data AYVAKIT COMMERCIAL GROWTH NEW PATIENT STARTS DURATION OF THERAPY ~65 new accounts activated in Q1 2022 ~70% share of new AdvSM patient starts ~

Slide 7: Retrospective analysis showed a longer OS among AYVAKIT patients
Retrospective analysis showed a longer OS among AYVAKIT patients A multi-center, global, observational, retrospective chart review study was conducted at 6 study sites (4 European, 2 US) to identify and collect data from AdvSM patients who received BAT. SM-AHN patients were identified using inclusio

Slide 8: Clinical Stage Growth
Clinical Stage Growth Rob T. Advanced cancer patient Not for promotional use.

Slide 9: Non-advanced SM patients have high medical need despite available therapies
Non-advanced SM patients have high medical need despite available therapies1 95% of SM cases driven by the KIT D816V mutation SYSTEMIC MASTOCYTOSIS SYMPTOMS2 Brain fog Pruritis, flushing and pigmented skin lesions Life-threatening organ infiltration and damage Unpredictable, life-threatening anaphyl

Slide 10: PIONEER Part 2 primary endpoint to be updated to mean change in TSS
PIONEER Part 2 primary endpoint to be updated to mean change in TSS 1. PIONEER Part 1. Based upon a data cutoff of March 12, 2020. TSS, total symptom score; FDA, Food and Drug Administration; ISM-SAF, Indolent Systemic Mastocytosis Symptom Assessment Form; SAP, statistical analysis plan; EMA, Europe

Slide 11: PIONEER Part 1 showed statistically significant difference in mean change in TSS
PIONEER Part 1 showed statistically significant difference in mean change in TSS between avapritinib and placebo 1. Hartmann K. et al. Avapritinib reduces cutaneous symptoms and mast cell burden in patients with indolent systemic mastocytosis in the PIONEER study. Presented at the European Academy o

Slide 12: Key secondary endpoints are important to fully characterize the impact of avapritinib
Key secondary endpoints are important to fully characterize the impact of avapritinib on patients with non-advanced SM 12 Not for promotional use. 1. Hartmann K. et al. Avapritinib reduces cutaneous symptoms and mast cell burden in patients with indolent systemic mastocytosis in the PIONEER study. P

Slide 13: PIONEER Part 2 topline on track for late summer 2022
PIONEER Part 2 topline on track for late summer 2022 TSS, total symptom score; QD, once daily; BSC, best supportive care; ISM, indolent systemic mastocytosis; QoL, quality of life; MC-QoL, Mastocytosis Quality of Life Questionnaire; PGIS, Patient's Global Impression of Symptom Severity; PGIS, Patien

Slide 14: Our portfolio of EGFR therapies is purpose-built to address medical needs
Our portfolio of EGFR therapies is purpose-built to address medical needs CS, C797S resistance mutation; Ex20in, activating exon 20 insertion mutations; LR, L858R activating mutation; TM, T790M resistance mutation. 14 Not for promotional use. Effectively block the EGFR pathway Establish 2L+ SOC with

Slide 15: BLU-945 potency and selectivity enable wide therapeutic index and broad EGFR coverage
BLU-945 potency and selectivity enable wide therapeutic index and broad EGFR coverage, with promising early clinical monotherapy data 15 aOne patient had two different DNA mutations in C797S. Note: reductions in individual variant allele fractions as shown; therefore, patients with multiple mutation

Slide 16: Phase 1/2 trials to rapidly generate data in broad populations
Phase 1/2 trials to rapidly generate data in broad populations, informing development and registration strategies PLANNED INITIATION OF PHASE 1/2 SYMPHONY / HARMONY TRIAL COHORTS 1L 2L+ 2023 701 + ADC All comer 945 + osi LR 701 + chemo All comer 701 + osi All comer Q2 2022 945 + osi LR + CS +/- TM 9

Slide 17: Opportunity to influence the treatment paradigm for more than 100K patients across CDK2-vulnerable cancers
Opportunity to influence the treatment paradigm for more than 100K patients across multiple CDK2-vulnerable cancers1 17 CDK-CYCLIN COMPLEXES REGULATE THE CELL CYCLE ABERRANT CYCLIN E (CCNE1) DRIVES CELL PROLIFERATION CDK4/6 Cyclin D CDK2 Cyclin E CDK2 Cyclin A CDK1 Cyclin A/B M G1 S G2 CELL DIVISION

Slide 18: BLU-222 is advancing toward clinical proof-of-concept
BLU-222 is advancing toward clinical proof-of-concept CCNE1, cyclin E; CDK4/6i, CDK4/6 inhibitor; ER, estrogen receptor. 18 Multiple dose cohorts* RP2D Combo with ER antagonist – ER+/HER2- breast Combo with CDK4/6i + ER antagonist – ER+/HER2- breast Monotherapy – CCNE1 tumors PHASE 2 EXPANSION (PLAN

Slide 19: Anticipated clinical data milestones over the next year
Anticipated clinical data milestones over the next year POC, proof-of-concept 19 Topline results, with additional detail presented at a medical conference at a later date Late summer 2022 2H 2022 1H 2023 Clinical data for BLU-222 Clinical data for BLU-451 Early clinical data for BLU-945+osimertinib,

Slide 20: Leading Precision Medicines Drug Discovery Platform
Leading Precision Medicines Drug Discovery Platform Diane L. Lung cancer patient Not for promotional use.

Slide 21: Research platform expansion to drive innovation & expanded productivity
Research platform expansion to drive innovation & expanded productivity 21 KINASE PLATFORM KINASE PLATFORM NEW PLATFORMS INTEGRATED PLATFORM CURRENT CAPABILITIES TARGETED PROTEIN DEGRADATION UNPARALLELED PRODUCTIVITY COMPLEMENTARY & SCALABLE NEW TARGET CLASSES LIBRARY & NEW TARGET DISCOVERY EXPANSIO

Slide 22: Business development plays a key role in value creation and long-term portfolio growth
Business development plays a key role in our company's value creation and long-term portfolio growth 22 Global Strategic Partnerships Access complementary expertise to maximize program value and global impact on patients Geographic Expansion Pioneering early development partnerships in China; expand

Slide 23: Strong financial position with total revenues estimated for 2022 between $180 and $200 million
Strong financial position with total revenues currently estimated for 2022 between $180 and $200 million 1. Includes stock-based compensation expense of $10.0M and $8.9M in the three months ended 3/31/22 and 3/31/21, respectively. 2. Includes stock-based compensation expense of $13.4M and $11.7M in

Slide 24: Blueprint is uniquely positioned with a diversity of significant growth drivers
Blueprint is uniquely positioned with a diversity of significant growth drivers Ongoing global collaboration with Roche and Genentech for the development and commercialization of GAVRETO. FDA, U.S. Food and Drug Administration; EC, European Commission; PDGFRA, platelet-derived growth factor receptor
Source: SEC EDGAR · 8-K filed Jun 9, 2022
More decks from Blueprint Medicines Corp
Q1 2025 Earnings Presentation14 slides · May 1, 2025
Q4 2024 Earnings Presentation12 slides · Feb 13, 2025
J.P. Morgan Healthcare Conference 202525 slides · Jan 13, 2025
Technical Presentation (April 2024)19 slides · Apr 25, 2024
J.P. Morgan Healthcare Conference 202425 slides · Jan 8, 2024
AAAAI 2023 Annual Meeting35 slides · Feb 27, 2023